Translational Neural Devices (R61/R33 - Clinical Trial Optional)
ID: 352612Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352612

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-151.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at supporting the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This grant program encourages investigators to conduct small clinical studies and translational activities, including non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals, with a focus on advancing innovative device designs that cannot be fully assessed through non-clinical methods. The program emphasizes health equity and diverse representation in research, with applications opening on April 29, 2024, and closing on January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-151-Full-Announcement.html
    Please provide the text you would like me to summarize.
    PAR-24-151.html
    The Department of Health and Human Services, through the National Institutes of Health, has issued a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of low-risk therapeutic and diagnostic devices for neurological disorders. This funding mechanism includes two phases: R61 for non-clinical testing leading to IRB approval and R33 for small clinical studies, requiring adherence to strict guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP). Key dates for application are set between May 2024 and January 2027, with applications reviewed for scientific merit and compliance with NIH policies.
    Similar Opportunities
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, including the implementation of clinical prototype devices, non-clinical safety testing, and obtaining necessary regulatory approvals. The program is structured in two phases: the UG3 phase focuses on non-clinical testing to secure regulatory approvals, while the UH3 phase supports clinical studies for market application. Eligible applicants include a diverse range of institutions, such as higher education, nonprofits, and small businesses, with a particular emphasis on underrepresented groups in science. Interested parties should note that the application deadline is September 27, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support the development of next-generation devices for recording and modulation in the human central nervous system. This initiative aims to facilitate translational activities and small clinical studies focused on therapeutic and diagnostic devices for CNS disorders, particularly those requiring Investigational Device Exemptions (IDE) for significant risk studies. The program emphasizes milestone-driven cooperative agreements, collaboration among diverse research teams, and the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to promote equitable access in research. With an annual budget of $10 million available for approximately 5 to 7 awards, interested applicants can find more information and apply starting April 29, 2024, by contacting NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional)" aimed at encouraging Small Business Concerns (SBCs) to develop therapeutic and diagnostic devices for disorders affecting the nervous and neuromuscular systems. This cooperative agreement program supports activities such as clinical prototype development, non-clinical safety testing, and preparation for regulatory submissions, facilitating the translation of innovative medical device technologies into clinical applications. The program emphasizes collaboration with NIH staff and aims to include diverse and underrepresented teams while adhering to rigorous compliance standards. Interested applicants must submit their proposals by September 28, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support clinical studies aimed at advancing next-generation devices for recording and modulation within the human central nervous system (CNS). This initiative encourages proposals for early-stage clinical investigations, including first-in-human studies, that focus on treating CNS disorders and enhancing understanding of brain functions, particularly through Significant Risk studies requiring FDA Investigational Device Exemptions (IDEs) for chronic implants. The NIH plans to allocate approximately $10 million annually to fund 5 to 7 projects, emphasizing the importance of collaborations with device manufacturers through a public-private partnership program, and requires a Plan for Enhancing Diverse Perspectives as part of the application. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 28, 2027.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at fostering the development of innovative brain stimulation devices or enhancing existing FDA-approved devices for treating mental health disorders. The initiative seeks applications from multi-disciplinary teams with expertise in neuroscience, engineering, clinical practices, and regulatory matters, focusing on creating devices that offer improved spatial and temporal resolution compared to current technologies. This funding opportunity is critical for advancing treatment methods in mental health care, with no budget limits as long as costs align with project needs, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation" (R21 Clinical Trial Optional). This initiative aims to support research that addresses ethical questions throughout the design, testing, and implementation phases of bionic and robotic devices, focusing on issues such as autonomy, informed consent, and equitable access to technology. A total of $2 million is available to fund 4-5 awards, with each project budget capped at $275,000 over two years. Interested applicants must submit their proposals by January 26, 2024, and can find additional details and guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding pharmacodynamic, pharmacokinetic, and in vivo efficacy studies for novel therapeutic agents targeting neurological and neuromuscular disorders. This funding opportunity encourages diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to develop innovative therapeutic approaches that demonstrate significant improvements over existing treatments. With funding available up to $499,000 per year and a maximum of $750,000 over three years, applicants must adhere to rigorous scientific standards and collaborate with multidisciplinary teams. Interested parties should note that the application deadline is October 21, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.